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It is nowadays well established that gap junctions are critical gatekeepers of cell proliferation, by controlling
the intercellular exchange of essential growth regulators. In recent years, however, it has become clear that
the picture is not as simple as originally anticipated, as structural precursors of gap junctions can affect cell
cycling by performing actions not related to gap junctional intercellular communication. Indeed, connexin
hemichannels also foresee a pathway for cell growth communication, albeit between the intracellular
compartment and the extracellular environment, while connexin proteins as such can directly or indirectly
influence the production of cell cycle regulators independently of their channel activities. Furthermore, a
novel set of connexin-like proteins, the pannexins, have lately joined in as regulators of the cell proliferation
process, which they can affect as either single units or as channel entities. In the current paper, these
multifaceted aspects of connexin-related signalling in cell cycling are reviewed.
Crown Copyright © 2010 Published by Elsevier B.V. All rights reserved.
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1. Introduction
The cell cycle is a well-orchestrated physiological process that
drives cell proliferation, cell growth and development. As such, the
somatic cell cycle encompasses themitotic (M) phase, subdivided into
the prophase, themetaphase, the anaphase and the telophase, and the
interphase. The interphase consists of a first gap (G1) phase, the DNA
synthesis (S) phase and the second gap (G2) phase, whereby the
former and the latter serve to prepare the cell for the S phase and the
M phase, respectively. Cells can exit the cell cycle and either enter a
quiescent (G0) phase, in which they can reside for an indefinite
period, or undergo terminal differentiation and/or apoptosis. Devia-
tion of physiological cell cycling, as a consequence of homeostatic
imbalance, may lead to uncontrolled cell proliferation activity which
ultimately might burgeon into carcinogenesis [1–4].
Progression through the subsequent cell cycle phases is coordinated
by a series of enzymes composed of a regulatory subunit and a catalytic
subunit, namely a cyclin protein and a cyclin-dependent kinase (cdk),
respectively. The activity of cdk enzymes is not only regulated by their
selective cooperationwith cyclins, but also by a number of other factors,
including kinases, phosphatases and members of the cdk inhibitory
protein/kinase inhibitor protein (Cip/Kip) family. In turn, these intrinsic
cell cycle regulators rely on commands triggered by extracellular
signals, such as growth factors [2,4,5]. At the intercellular signalling
platform, control of the cell cyclemachinery ismainly accommodatedby
gap junctions, a group of specialized cell-to-cell junctions composed of
connexin proteins [6–10].
In the present paper, a state-of-the-art overview of the role of
connexin-related signalling in cell cycling is provided. In the first part,
basic concepts with respect to the biology of connexin channels are
reviewed. In the second part, the outcome of cell cycling on connexin-
related signalling is discussed, whereas the inverse event, namely the
effects of connexin-related signalling on cell cycling, are extensively
outlined in the third part. Overall, particular attention is paid to the
molecular mechanisms that underlie this interrelationship.
2. Connexins and their channels: basic concepts
2.1. Structural properties
Morphologically, gap junctions appear as plaques at the cell plasma
membrane surface and arise from the docking of two hemichannels
(connexons) of adjacent cells, which on their turn are composed of six
connexin (Cx) units. The connexin family comprises as many as twenty
isoforms in mammals. They all share an identical molecular architecture,
consisting of four membrane-spanning domains, two extracellular loops,
one intracellular loop, one cytoplasmic N-terminal tail and one
cytoplasmic C-terminal tail (Fig. 1). Connexins are named after their
molecularweight and are expressed in a tissue-specific and even in a cell-
specificmanner. Thus, themost abundant connexin species in the human
body has a predicted weight of 43 kDa and is therefore designated Cx43
[6,7,11–13]. Connexins interact with a number of other cellular proteins,
including scaffolding proteins, junctional proteins, cytoskeletal proteins,
trafficking regulators, posttranslational modifiers and growth regulators,
all of which may affect connexin metabolism and functionality [11,14].
2.2. Functional properties
Gap junctions provide an essential pathway for the intercellular
exchange of small and hydrophilic molecules, including glucose,
glutamate, glutathione, cyclic adenosine monophosphate (cAMP), aden-
osine triphosphate (ATP), inositol trisphosphate (IP3), and ions, like
calcium, sodium and potassium [15,16]. The biophysical permeation
characteristics of these substances rely on the nature of the connexin
species that form the gap junction [15,17]. For instance, ATP is more able
to pass through Cx43-based gap junctions, compared with channels
composed of Cx32 [18]. Obviously, numerous, if not all, physiological
processes are driven by the substances that are conveyed via these
channels, and hence gap junctional intercellular communication (GJIC) is
considered as a keymechanism in themaintenance of tissue homeostasis
[6,7,13,16]. In the last decade, it has become clear that hemichannels in
Fig. 1.Molecular architecture of gap junctions. Gap junctions are grouped in plaques at the cell plasma membrane surface and are composed of twelve connexin proteins, organized
as two hexameric hemichannels or connexons of two apposed cells. The connexin protein as such is organized as fourmembrane-spanning domains (TM1-4), two extracellular loops
(EL1-2), one cytoplasmic loop (CL), one cytoplasmic amino tail (NT) and one cytoplasmic carboxy tail (CT).
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non-junctional areas at the cell plasma membrane surface also can
function as transmembrane channels. In fact, connexons foresee a
pathway for communication between the intracellular compartment
and the extracellular environment. The substances that travel through
hemichannels are quite similar to those implied in GJIC, namely ATP,
nicotinamide adenine dinucleotide (NAD+), glutamate, glutathione and
prostaglandins [12,16,19–21].
2.3. Regulatory properties
A labyrinth of mechanisms underlies the regulation of the connexin
life cycle and activity. Instant control (i.e. second/minute range) of
connexin channel functionality by the process of channel gating is
governed by a number of factors, including transmembrane voltage,
calcium ions and hydrogen ions [6,7,13]. Undoubtedly, phosphorylation
has gained most attention in this respect. All connexins, with the
exception of Cx26, are phosphoproteins. The outcome of the phosphor-
ylation event, mainly occurring at the C-terminal connexin tail, depends
on both the identity of the connexin species and the kinase type [22,23].
Regulation of GJIC and hemichannel activity over the long-term (i.e.
hour range) basically concerns peritranscriptional control of connexin
expression. The structure of most connexin genes is rather simple and
consists of a first exon, containing the 5′-untranslated region which is
separated by an intron froma secondexon, bearing the complete coding
sequence and the 3′-untranslated region [11,24,25]. Connexin gene
transcription is ruled by conventional cis/trans actions, involving both
ubiquitous transcription factors, like specificity protein 1 (Sp1) and
activator protein 1 (AP-1), and tissue-specific transcription factors, such
as hepatocyte nuclear factor 1 [25]. Epigenetic mechanisms, including
histone acetylation and DNA methylation, predominate the pretran-
scriptional platform of connexin expression [6,25]. Recently, microRNA
species have been described as novel regulators of connexin expression
at the posttranscriptional level [26–31].
3. Connexins as sensors of cell cycling
3.1. Effects of cell proliferation on connexin-related signalling
It has been first reported already a few decades ago that mitotic
cells, such as in early mouse and Xenopus laevis embryos, display
reduced gap junction-based intercellular coupling, not only among
themselves, but alsowith interphasic cells [32–37]. In course of time, a
broad variety of empirical models has been used to scrutinize the
physiological connection between connexin-related signalling and
cellular proliferation, though a frequently addressed experimental
setting includes the regenerating liver. The adult liver displays very
low proliferative activity under normal conditions. Upon partial
hepatectomy, however, the remaining liver lobes start to grow and
the original size becomes restoredwithin aweek [38,39]. Most reports
describe transiently increased GJIC and gap junction numbers in the
G1 phase, followed by a drastic decrease upon initiation of the S phase
of the hepatocyte cell cycle. Similar alterations are observed at the
level of Cx32 expression and in many cases in Cx26 levels, whereas
Cx43 largely remains unaffected [40–51]. Other connexins present in
hepatic tissue, including Cx37 and Cx40, are clearly upregulated
during liver regeneration [52]. Analogous findings are produced in in
vitro systems of hepatocyte proliferation, namely mitogen-stimulated
primary hepatocyte cultures [40–44,53,54]. Differential expression
patterns of connexins, in casu Cx37, Cx39, Cx40, Cx43 and Cx45, are
also noticed during rat muscle regeneration following crush injury
[55] and notexin-induced myonecrosis [56,57]. In regenerating rat
tracheal epithelium, gap junction numbers increase in the interphase
and decrease during the M phase [58]. Cultured normal human
mammary epithelial cells display moderate Cx26 production during
the G1 phase and the early S phase, but high levels in the late S phase
and the G2 phase. Cx43, by contrast, is constitutively expressed at a
uniform low level throughout the cell cycle [59]. In proliferating cells
of the murine neocortex, Cx26 expression increases from the S phase
to the early G1 phase and remains moderately high throughout the
rest of the cell cycle. Cx43 production is highest in the S phase and the
G2 phase and decreases towards the G1 phase. This corresponds with
maximal coupling during DNA synthesis and the G2 phase, uncou-
pling in the M phase and recoupling in the G1 phase and the S phase
[60,61]. With respect to the mitotic process as such, GJIC drastically
drops at the onset of the prophase, and remains low throughout the
metaphase, the anaphase and the telophase. Resumption of GJIC
between newly divided cells and surrounding cells occurs slowly after
cytokinesis [34,62]. A plethora of additional reports have described
alterations in GJIC and connexin expression during cell cycling in
somatic cells both in physiological and pathological conditions, and
although conflicting results have been published [15,63–68], the
overall outcome of these studies is that an inverse relationship exists
between cell proliferation and gap junction activity [69–74]. A
particular case includes the meiotic cell cycle in germ cells, especially
in oocytes, which is initiated during embryonic life. A first meiotic
block occurs at a G2-like phase of the cell cycle (i.e. the prophase of
the first meiosis), and is associated with the establishment of GJIC.
Upon gonadotropin stimulation during puberty, the oocytes resume
meiosis, which is preceded by a drastic downregulation of Cx43
expression and GJIC. This allows completion of the first meiotic
division, followed by the second metaphase, where the oocytes
remain arrested until activation by a spermatozoon [75,76].
3.2. The mechanisms beyond
3.2.1. Transcriptional modulation of connexin expression
A clear-cut way to interfere with connexin-related signalling upon
cell growth commitment concerns direct modulation of the expres-
sion of its constituents at the most upstream regulatory level. A
myriad of cell proliferation-related signalling cascades are known to
affect connexin gene transcription. The mitogen-activated protein
kinase (MAPK) signal transduction pathway has received consider-
able attention in this context. As much as six different MAPK cascades
have been characterized in mammals, of which the most extensively
studied ones include the extracellular regulated kinase (ERK)
pathway, the jun NH2 terminal kinase (JNK) pathway and the p38
MAPK pathway. These signalling cascades can be activated by a
number of extracellular stimuli, such as hormones and growth factors,
and can influence the transcription of cell cycle genes in a
straightforward manner by triggering phosphorylation of the proto-
oncogenes c-jun and c-fos [77,78]. The latter dimerize to form the
transcription factor AP-1, which is known to bind the promoter region
of the Cx43 gene [25]. Heat shock protein 90 and c-myc also directly
interact with the Cx43 gene promoter upon induction of MAPK
signalling [79]. Despite the generally established negative correlation
between cell proliferation and GJIC, however, MAPK pathways
preferentially upregulate Cx43 gene transcription. Indeed, induction
of cell proliferation by angiotensin II and insulin-like growth factor 1
in human saphenous vein smooth muscle cell cultures is associated
with increased GJIC and Cx43 expression, whereby the latter is
mediated by ERK1/2, p38 MAPK and c-jun [80,81]. Both insulin-like
growth factor 1 and phenylephrine also upregulate Cx43 gene
transcription in an ERK/p38 MAPK-dependent way in human corneal
epithelial cells [82] and neonatal rat cardiomyocytes [83], respective-
ly. Likewise, stimulation of cell proliferation by basic fibroblast growth
factor (FGF2) in cultures of mouse cortical neural progenitor cells is
accompanied by enhanced cell-to-cell coupling and an elevated Cx43
mRNA content, which is facilitated by ERK1/2 [63,84]. By contrast,
transforming growth factor-β suppresses proliferation of murine
mammary gland epithelial cells, but still Cx43 gene transcription
becomes promoted in a p38 MAPK/c-jun-dependent manner [85]. A
MAPK signalling cascade is also activated by luteinizing hormone
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upon meiotic resumption in rat oocytes, though this is allied with
decreased Cx43 mRNA levels [75,86].
3.2.2. Posttranslational modulation of connexin channel activity
At the utter downstream platform of connexin expression,
phosphorylation represents a major mechanism for regulating
connexin-based signalling during cell cycling. Thus, upon prolifera-
tion of human T cells, Cx43 phosphorylation at serine368 strongly
increases [87]. In serum-stimulated rat liver cells, progression from
the G0 phase to the S phase is related to protein kinase C (PKC)-
dependent phosphorylation of Cx43 on serine residues and disruption
of GJIC, but not with changes in Cx43 mRNA content [88]. In primary
cultures of neonatal rat cardiomyocytes, PKC-mediated phosphoryla-
tion of Cx43 at serine262 in response to growth factor stimulation was
found to regulate DNA synthesis [89,90]. PKC also phosphorylates
Cx43 at serine368 during the S phase and the G2/M cell cycle
transition in normal rat kidney epithelial cells. This is associated with
cytosolic redistribution of Cx43 and subsequent reduced GJIC [91].
Another kinase involved in connexin phosphorylation during cell
cycling is cdk1/cyclin B complex, which controls the G2/M cell cycle
transition. In several cell types, cdk1/cyclin B-mediated phosphory-
lation of Cx43 is highest at the G2/M cell cycle transition, yielding a
mitosis-specific Cx43 phosphoform, called Cx43m [36] or Cx43P3
[33,92]. This particular Cx43 phosphoform preferentially localizes in
the cytosol, thus explaining the reduced GJIC activity observed in
mitotic cells. Melchheier and co-workers further showed that the cell
division cycle 25A phosphatase, known to regulate cdk1 activity and
the G1/S cell cycle transition, is involved in the ERK1/2-dependent
phosphorylation of Cx43 and GJIC during cell cycling [93]. MAPK
members can indeed directly phosphorylate connexin proteins in
addition to their acknowledged effects on connexin gene transcrip-
tion. For instance, the dynamic changes in gap junction formation
during hepatocyte proliferation in vivo and in vitro are controlled, at
least in part, by p38 MAPK-mediated phosphorylation of Cx32
[42,44,54]. In rat oocytes, luteinizing hormone disrupts GJIC prior to
meiotic resumption, which is associated with ERK1/2-assisted
phosphorylation of Cx43 at serine255, serine262, serine279 and
serine282 [94,95]. A vast number of studies have outlined phosphor-
ylation of Cx43 byMAPKmembers and consequent downregulation of
GJIC, whether or not directly induced by growth factors [93,96–103].
Epidermal growth factor (EGF) activates cell proliferation and
simultaneously inhibits GJIC in mouse embryonic stem cells. In fact,
EGF, after binding to its receptor, triggers PKC, ERK1/2 and p38 MAPK
which subsequently phosphorylate Cx43. This results in elevated
levels of c-fos, c-jun and c-myc that on their turn activate the
expression of cyclin D1, cyclin E, cdk4 and cdk2 and inactivate the
production of the cell cycle inhibitors p21Cip1 and p27Kip1 [104]. A
similar mechanism underpins the repressing effects of the adenosine
analogue 5′-N-ethylcarboxamide on GJIC in these cells. Thus, 5′-N-
ethylcarboxamide induces Cx43 hyperphosphorylation, involving
ERK, p38 MAPK and JNK pathways, which results in the down-
regulation of GJIC. The outcome of this signalling cascade is an
induction of proliferation, as may be evidenced by increased
expression of cdk2, cdk4, cyclin E, cyclin D1 and an elevated S phase
cell population number [105]. Interestingly, growth factors can have
differential and even opposite effects on gap junctions and hemi-
channels. FGF2, for instance, inhibits gap junction activity but
stimulates ATP release through hemichannels in Cx43-overexpressing
rat glioma cells [106]. Reverse regulation of gap junctions and
hemichannels composed of Cx43 has also been observed in primary
mouse astrocyte cultures and is mediated by p38 MAPK [107]. In
addition, activation of p38 MAPK underlies the FGF1-induced
increased membrane permeability via Cx43-based hemichannels in
human cervical cancer cells [108]. It has been suggested that
switching between GJIC and hemichannel signalling through different
regulation may serve to optimize cellular responses to newly
occurring (patho)physiological conditions [106], in casu cell growth.
4. Connexins as regulators of cell cycling
4.1. Effects of connexin-related signalling on cell proliferation
Evidence indicating an active role for connexins and their channels in
cell cycle control mainly comes from studies in which connexin
expression and activity have been altered by genetic approaches. An
abundance of reports have indeed described inhibition, mostly G1/S cell
cycle arrests, or induction of (tumor) cell growth upon overexpression or
genetic ablation of connexins, respectively [109–148]. Furthermore,
expression of connexins protects against spontaneous or chemically
induced tumorigenesis and accordingly connexin genes are considered as
tumor suppressors [123,136,140,149–153]. This negative cell growth
control by connexins seems to be a specific rather than a general
phenomenon, as not all connexin genes induce cell cycle arrests following
their forced expression in cells [115,154–157]. In contrast, several studies
have demonstrated that the presence of connexins is indispensable for
the enrollment of cell proliferation [158–170]. On top of the already
complex nature of the link between connexins and cell cycling comes the
issue of the relative importance of their physiological interrelationship. In
this respect, Ott and colleagues [171] reported that genetic depletion of
Cx26 and Cx32 in hepatocytes does not lead to increased spontaneous
liver tumor formation, but only slightly increases the basal proliferation
rate. In the regenerating liver of Cx32 knock-out mice, the G0/S cell cycle
transition, and thus the proliferative activity of the hepatocytes, is not
promoted, but the extent of the synchronous initiation and terminationof
DNA synthesis is altered [48,150]. Likewise, cultured astrocytes from
Cx43-deficientmice display delayed onset of growth, but the growth rate
as such is not altered [168]. Based on these facts, reduction of connexin-
related signalling does not provide a direct signal for cells to divide, but
rather permits cell cycle progression upon mitogenic stimulation. In this
view, gap junction activity seems to be coordinated with cell growth and
serves a purpose other than triggering proliferation. Such purpose may
include the functional segregation of themetabolic pools in dividing cells
from their quiescent neighbours in order to avoid disruption of the
homeostatic balance [40,41,172]. A conflicting concept states that
connexins fulfil a determinate function in cell cycle control, thus
exceeding a merely assisting role in cell growth progression. In support
of this idea are not only the numerous aforementioned genetic studies,
showing a causal inverse link between cell connexin expression and cell
growth control [109–147], but also for instance the finding that in
primary cultures of Cx32 knock-out mouse hepatocytes, most cells enter
the S phase without mitogenic stimulation, whereas their wild-type
counterparts are blocked in the G1 phase in these conditions [173].
4.2. The mechanisms beyond
4.2.1. Mechanisms related to connexin channel formation
4.2.1.1. Gap junction-dependent mechanisms. It has been demonstrated
on several occasions that chemical inhibition of GJIC affects cell
cycling. The prototypical gap junction blockers 18-α-glycyrrhetinic
acid, heptanol and carbenoxolone were indeed found to suppress
mitotic clonal expansion in cultures of mouse adipocytes [174], in
human placental villous explant cultures [175] and in rat retinal cells
in vivo [176], respectively. Carbenoxolone also attenuates DNA
synthesis in cultures of rat hepatic stellate cells, accompanied by the
decreased expression of cyclin D1, cyclin D2, cdk2, cdk4 and cdk6
[177]. Cisplatin induces gap junction closure in human lung
fibroblasts which is associated with a G1/S cell cycle arrest, elevated
p53 expression and initiation of premature senescence [178]. On
the other hand, 18-α-glycyrrhetinic acid promotes cell cycling in
cultures of rat Sertoli cells [179] and enhances the ability of murine
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megakaryocytes to stimulate proliferation in co-cultured osteoblasts
[180]. Furthermore, exposure of primary cultures of rat astrocytes to
carbenoxolone increases the S phase, the G2 phase and the M phase
cell cycle population numbers and simultaneously decreases the
amount of G1 phase and G0 phase cells. This is allied with increased
phosphorylation of retinoblastoma protein and enhanced expression
levels of cyclin D1 and cyclin D3 [181]. In rat ovarian follicles,
carbenoxolone triggers reinitiation of meiosis and oocyte maturation
[182]. Clearly, gap junctions foresee a pathway for the direct
intercellular exchange of positive and negative cell growth regulators.
However, the biochemical identity of these messengers largely
remains to be clarified. A first plausible candidate in this context
includes calcium. Gap junctional propagation of calcium waves in
proliferating human keratinocytes is much lower in comparison with
that in differentiating keratinocytes in the upper layers of the skin
[183]. Additionally, increased intercellular travelling of calcium via
gap junctions is thought to underlie the G0/G1 cell cycle block induced
by fucoxanthin in human hepatoma cells [184]. A second possible cell
growth messenger is cAMP, which is an acknowledged enhancer of
p27Kip1 production [142,144]. The cAMP content is highest in the G1
phase and decreases prior to S phase entry [185], thus correlating with
the downregulation of GJIC at the G1/S cell cycle transition observed
in many cell types, such as in proliferating hepatocytes [40–51]. In
oocytes, cAMP and guanosine-3′,5′-cyclic monophosphate, both
passing through gap junctions, have been found to maintain meiotic
arrest [186,187]. A third aspirant growthmessenger is IP3, a key player
in calcium signalling and therefore a determinant of cell cycling [188].
In this context, Stains and Civitelli showed the existence of connexin
response element (CxRE) in the promoter region of the rat osteocalcin
gene, which is controlled by Sp1 transcription factors. Upon
extracellular growth stimulation (“gap junction-independent primary
response”), an unknown second messenger, possibly IP3, propagates
by means of gap junctions (“gap junction-dependent primary
response”) and subsequently triggers the ERK and phosphoinositide
3-kinase/protein kinase B signalling cascade. Activated ERK then
translocates to the nucleus, where it phosphorylates Sp1. The latter
binds to the CxRE module, resulting in osteocalcin gene transcription
and thus bone formation [189–191].
4.2.1.2. Hemichannel-dependent mechanisms. As also holds true for their
full channel cognates, inhibition studies frequently point to roles for
connexons in cell cycle management. The Cx43 hemichannel inhibitor
43Gap27, thatmimics an amino acid sequence in the secondextracellular
loopof theCx43protein, reduces proliferationof activatedhumanT cells,
as evidenced by an increased amount of G0/G1 phase cells and a
decreased S cell population number [87]. By contrast, 43Gap27 lowers
dye uptake through Cx43 hemichannels which coincideswith enhanced
wound healing and proliferation of human keratinocytes and skin
fibroblasts in vitro and ex vivo [192]. Such findings are further sub-
stantiated by applying genetic strategies. Artificial introduction of the
Cx32 gene or the Cx43 gene into rat pheochromocytoma cells and
subsequent exposure to nerve growth factor results in enhanced neurite
outgrowth. However, this does not depend on the establishment of GJIC,
but relies on extracellular ATP release through connexin hemichannels
[193]. Upon transfection of mutated Cx30 in human cervical cancer cells
and Xenopus laevis oocytes, the ability to form intercellular channels is
retained, but leaky connexin hemichannels are observed. Cx30 muta-
tions are known to be involved in a genetic disorder called hidrotic
ectodermal dysplasia, also known as the Clouston syndrome, which is
characterized by palmoplantar hyperkeratosis. It is believed that in-
creased ATP release through leaky Cx30 hemichannels interferes with
paracrine signalling in the epidermis, ultimately leading to keratinocyte
hyperproliferation [194]. From such studies, it is clear that connexin
hemichannels may fulfil crucial and quite specific functions in cell cy-
cling. In the developing neocortex of rat, spontaneous intercellular
calcium waves propagate through radial glial cells and modulate cell
proliferation. These calciumwaves, involving the release of calcium from
IP3-sensitive intracellular stores, are mediated by extracellular ATP and
are critical to drive G1 phase cells into the S phase. Connexin
hemichannels are opened upon initiation of DNA synthesis, followed
by the extracellular release of ATP and the increase in the intracellular
calcium concentration in neighbouring radial glial cells that linger in the
G1/S transition [195]. Spontaneous rise in intracellular calcium concen-
tration also triggers Cx43 hemichannel opening in developing retinal
epithelium cells. Released ATP binds to purinergic receptors of adjacent
retinal pigment epithelium cells and causes an increase in the
intracellular calcium concentration and progenitor cells in the neural
retina, resulting in increased cell proliferation [196]. Furthermore,
hemichannels and gap junctions composed of Cx43 modulate the rate
of the interkinetic nuclear movement (i.e. the back-and-forth migration
of nuclei across the proliferative zone during the G1 phase, the G2 phase
and the M phase of the cell cycle) in retinal progenitor cells, which is an
essential determinant of cell cycle duration [197]. Recently, an identical
role for both channel types has been described during interkinetic
nuclear migration inmurine forebrain precursors, whereby it was found
that blocking Cx43 channels leads to phosphorylation of the cell division
control protein 42 [198]. Besides ATP, hemichannels also control the
extracellular liberation of NAD+, known to influence proliferative
activity. In fact, released NAD+ is processed by the ectoenzyme cluster
of differentiation 38 (CD38), an integral membrane protein possessing
an active extracellular site, yielding cyclic ADP-ribose (cADPr). cADPr re-
enters the cell or moves to another cell and acts as a second messenger
by inducing calcium release from the endoplasmic reticulum. A similar
pathway is equally observed within individual cells. In this case, both
CD38 and connexons are located in intracellular vesicles. Upon
hemichannel-mediated introduction of NAD+, cADPr is produced in
the vesicle lumen and becomes released in the cytosol via CD38, again
altering the calcium concentration [199–203]. Franco and co-workers
[201] showed that an increase of the cytosolic calcium concentration,
initiated by either enhanced exchange of NAD+ (Cx43 hemichannel-
mediated) and cADPr, or an extracellular exchange of both signalling
metabolites, results in increased cell proliferation in mouse fibroblast
cultures via shortening of the S phase.
4.2.2. Mechanisms not related to connexin channel formation
4.2.2.1. Modulation of the expression of cell growth regulators. While
genetically interfering with connexin expression, it has been regularly
observed that effects on cell growth can occur independently of
changes in channel activity, in casu GJIC [112,114,118,121,122,142–
144,148,156,160,204–215]. In consistence with these observations is
the fact that connexin proteins, as single entities, can affect the
production and/or activity of cell growth regulators, including p27Kip1,
cyclin A, cyclin D1, cyclin D2, cdk5, cdk6, ERK1/2, signal transducer and
activator of transcriptionprotein 3, Src, humanEGF receptor 2, FGF1 and
FGF receptor 3 whichmay [122,142–144,152,155,169,216–221] or may
not [122,142–144,148,156,160,209,212,222,223] be related to the
presence of gap junction activity. A most representative study in this
respect includes the works of Zhang and colleagues. They showed that
forced expression of Cx43 causes a G1/S cell cycle arrest in human
osteosarcoma cells, which is associated with accumulation of hypopho-
sphorylated retinoblastoma protein, decreases in cdk2 and cdk4
activities and increased p27Kip1 expression. The latter is, at least in
part, a result of the reintroduction of gap junctions, which allow the
intercellular flux of cAMP, being an enhancer of p27Kip1 synthesis.
Simultaneously, Cx43 promotes the degradation of the S phase kinase-
associated protein 2, a protein that is involved in p27Kip1 ubiquitination.
The overall interplay between these GJIC-dependent and GJIC-indepen-
dent mechanisms results in the accumulation of p27Kip1 and thus a
proliferative block [142–144]. The precise mechanisms beyond the gap
junction-unrelatedactions of connexinson theexpressionof cell growth
regulators remain, however, obscure. It has been suggested that
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connexins can directly affect gene transcription. Connexins, or at least
specific parts of thesemolecules, have been reported to reside in the cell
nucleus. Upon its forced expression in human cervical cancer cells [206],
human embryonic kidney cells [206] and mouse neuroblastoma cells
[215], the C-terminal tail portion of the Cx43 molecule becomes
diffusely located in the cell, including the nuclear compartment,
which could underlie the subsequent inhibition of cell growth. Likewise,
human cervical cancer cells transfected with mutated Cx43, bearing
point mutations in the second extracellular loop region, do not display
GJIC because of aberrant cytosolic localization of Cx43, though cell
growth is still suppressed [112]. Omori and Yamaski [115], however,
found that mutants of both Cx32 and Cx43, lacking their C-terminal tail,
but not their wild-type counterparts inhibit cell proliferation in this
same cell type, suggesting that structural regions other than the C-
terminal portion are critical for connexin-mediated control of cell
growth. Alternatively, the connection between connexins and the
production of cell growth regulatory substances could also be more
indirect and may arise from the interaction between connexins and a
number of key homeostasis regulators. This set of mechanisms will be
addressed in the following paragraph.
4.2.2.2. Interaction with cell growth regulators
4.2.2.2.1. ß-Catenin. Two pools of ß-catenin are found in the cell,
namelyat the cell plasmamembrane surface,where it serves as abuilding
stone for adherens junctions, and in the cytosol, where it functions as a
regulatory component of the canonical Wingless-Int (Wnt) signalling
pathway. In the absence of Wnt signals, being secreted glycoproteins,
cytosolic ß-catenin forms a complexwith the adenomatouspolyposis coli
tumor suppressor, axin and glycogen synthase kinase-3ß. This complex
phosphorylates ß-catenin, serving as a trigger to induce its degradation.
Upon the binding of a Wnt ligand to its receptor at the cell plasma
membrane surface, the degradation complex becomes destabilized,
resulting in cytosolic ß-catenin accumulation. The latter then moves to
the nucleus, where it binds to transcription factors belonging to the
family of the T cell factors/lymphoid enhancer factors. This complex
subsequently activates the transcription of a number of genes that code
for G1/S cell cycle regulators, such as cyclin D1 and c-myc [224–228].
Furthermore, Wnt signalling also controls the G2/M transition of the cell
cycle [229]. It has been reported that ß-catenin interacts with Cx43 at
cell-cell contact areas, and by doing so, Cx43 reduces the total amount of
ß-catenin that is available forWnt signalling, thus leading to inhibition of
cell proliferation [230,231]. Interestingly, the Cx43 gene itself has been
identified as a downstream target forWnt signalling, which suggests that
Cx43 can regulate its own production [230,232]. In fact, activation of the
Wnt signalling cascade by a number of stimuli resulted in increased Cx43
expression and in some cases, this was associated with enhanced GJIC
and proliferative potential [230,232–242].
4.2.2.2.2. E-cadherin. Despite the acknowledged colocalization of
gap junctions with adherens junctions and in contrast to ß-catenin,
the direct physical interaction between connexins and cadherins still
is a matter of debate [14,243–246]. Nevertheless, intimate crosstalk
between both cell junction types is critical for their proper formation,
localization and function [236,247–256]. In regenerating mouse
hepatocytes, for instance, the assembly of adherens junctions
composed of E-cadherin, and thus the presence of cell adhesion, is
indispensable for the establishment of Cx32-based gap junctions
[257]. Vice versa, transfection of human liver cancer cells with the
Cx26 gene reduces cell growth, which is associated with induced E-
cadherin expression and thereby the formation of cell adhesion
complexes [138,139]. In a similar way, genetic introduction of Cx43 in
human lung cancer cells activates E-cadherin production and causes a
G1/S cell cycle arrest [258]. In addition, overexpression of N-cadherin
and Cx43 in human embryonic kidney cells synergistically suppresses
cell proliferation by prolonging the G2/M cell cycle transition. This is
accompanied by elevated expression of p21Cip1, which relies on Wnt
signalling, and a concomitant decline in cdk1 activity [231].
4.2.2.2.3. Nephroblastoma overexpressed protein. Ectopic expression
of Cx43 in glioma cells increases GJIC and decreases cell growth in
vitro and in vivo, coinciding with elevated expression of the cysteine
rich 61 (Cyr61) protein and the nephroblastoma overexpressed
(NOV) protein. The latter hereby colocalizes with Cx43 gap junction
plaques at the cell plasma membrane surface [259–262]. It has indeed
been shown that NOV interacts with Cx43, but not with other
connexins, including Cx32 and Cx40, in glioma cells and choriocar-
cinoma cells [263–265]. NOV is a member of the CCN family, which is
an acronym for Cyr61, connective tissue growth factor (CTGF) and
NOV. CCN proteins are multimodular regulators known to play roles
in a number of biological processes [266]. NOV itself is involved in cell
cycle control and inhibits proliferation. It is believed that Cx43 is able
to regulate cell growth by increasing NOV production, the concom-
itant shift of NOV localization from the nucleus to the cell plasma
membrane surface and the direct binding of NOV to Cx43 [263–265].
4.2.2.2.4. Zonula occludens 1-associated nucleic acid binding protein.
Cx30, Cx32, Cx43 and Cx47 all colocalize with ZO-1-associated nucleic
acid binding protein (ZONAB) in rat brain [267,268]. ZONAB is a
transcription factor that binds to inverted CCAAT-box sequences,
found in the promoter region of genes coding for several cell growth
regulators, including cyclin D1 and the proliferating cell nuclear
antigen [269]. As the name suggests, ZONAB interacts with zonula
occludens 1 (ZO-1), being a tight junction component. Interaction
between ZONAB and ZO-1, and thus cell growth control, occurs in a
cell density-dependent manner. Indeed, cells grown at low density
display low ZONAB–ZO-1 interaction and a high proliferative
potential. In these cells, ZONAB accumulates in the nucleus, where it
represses the gene transcription of human EGF receptor 2, a receptor
tyrosine kinase involved in cell growth [270,271]. ZONAB also binds to
a number of other proteins, whichmay directly or indirectly modulate
its transcriptional activity in relation to cell proliferation, including
cdk4 [270,271], ras-related protein [272], heath shock protein 4A
[273], symplekin [274,275] and the guanine nucleotide exchange
factor H1/Lbc's first cousin [276].
4.2.2.2.5. Zonula occludens proteins. Apart from the indirect contact
via ZONAB, ZO-1 as well as ZO-2 also directly interact with Cx43. This
process is subject to cell cycle phase-specific control. Thus, Cx43 has a
strong binding preference for ZO-1 during the G0 phase, whereas
Cx43-ZO-2 interaction occurs equally during the G0 phase and the S
phase in rat kidney epithelial cells [277]. Similar to ZO-1, ZO-2 binds
to transcription factors, in casu c-jun, c-fos and CCAAT enhancer
binding protein [278] and thereby shuttles between the cell periphery
and the nucleus [279–281]. As such, ZO-2 was found to downregulate
cyclin D1 gene transcription [281,282], to increase cyclin D1 protein
degradation [281] and ultimately to inhibit cell cycling at the G0/G1
transition [281].
4.2.2.2.6. Discs-large homolog 1 protein. In hepatocytes, Cx32
interacts with the scaffolding protein Dlgh1 (discs-large homolog 1).
Dlgh1 acts as a tumor suppressor protein and its presence at the cell
plasmamembrane surface, bound to Cx32, is associatedwith a cell cycle
block at the G0/G1 transition. Upon its release, occurring following
downregulation of Cx32 expression, Dlgh1 translocates to the cell
nucleus, where its actions lead to increased proliferative activity.
Therefore, maintaining Dlgh1 at the cell plasma membrane surface
may be a regulatory mechanism by which Cx32 controls hepatocyte
proliferation [283].
4.2.2.2.7. Involvement of pannexin-related signalling. Another level of
promiscuity in the complicated relationship between connexin-related
signalling and cell cycling is formed by pannexins. This recently
discovered protein family yet consists of three members (Panx1-3) in
rodents and man. Despite the lack of sequence homology between
connexins and pannexins, they share a similar topology and also display
cell-specific expression patterns. Pannexins, however, tend to gather as
hexameric hemichannels, rather than in a gap junction configuration. Like
their connexin counterparts, pannexin hemichannels allow the passive
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flux of small molecules, such as ATP, between the cytosol and the
extracellular environment. The permeability of pannexin hemichannels
can be altered by a number of stimuli, including changes in intracellular
calcium and hydrogen concentration, and membrane potentials
[19,284,285]. Several lines of evidence suggest a role for pannexins in
cell proliferation. Following induced expression in rat glioma cells, Panx1
becomes located in the Golgi apparatus and at the cell plasmamembrane
surface. This results in increasedGJIC, reducedproliferative activity in vitro
and suppressed tumor growth in vivo [286]. In a similar way, Panx2
behavesas anegative growth regulatoruponexogenous introduction into
these cells, both in vitro and in vivo. Panx2 is hereby predominantly
localized in the cytoplasm and does not affect GJIC or the production of
Panx1 and Cx43 [287]. Pannexins also affect proliferative events as
hemichannel entities, such as during adaptive immune response. Upon
T cell activation by binding to an antigen presenting cell, ATP becomes
released through Panx1 hemichannels in a calcium-dependent manner.
Released ATP from T cells not only binds to purinergic receptors on
antigen presenting cells but also to own purinergic receptors. The latter
activates aMAPKsignalling cascade and serves as anautocrine costimulus
for T cell proliferation [288]. In a more pathological context, Panx1
hemichannels are involved in cardiac fibrosis induced by pressure
overload. Upon mechanical stress, ATP and uridine diphosphate are
released from cardiac myocytes via Panx1 hemichannels, leading to
stimulation of purinergic receptors that subsequently activate guanine
nucleotide-binding proteins. Consequently, the expressionof a number of
fibrogenic factors becomes induced in cardiomyocytes, including trans-
forming growth factor-β and connective tissue growth factor. These
fibrogenic factors evoke activation and proliferation of cardiac fibroblasts
in a paracrine manner [289]. Recently, Iwamoto and colleagues showed
that Panx3 functions as a hemichannel following transfection in murine
chondrocytic cells, whereby intracellular ATP and cAMP levels become
reduced. This impedes phosphorylation and thus activation of the cAMP
response element binding transcription factor. The latter is a downstream
effector of the parathyroid hormone/protein kinase A/cAMP signalling
cascade that regulates cell growth in chondrocytes. As a result of its
inactivation, the cAMP response element binding transcription factor can
no longer bind to its target genes, including the cyclin D1 and cyclin A
genes, and cell proliferation becomes suppressed [290].
5. Conclusions and perspectives
Tissue homeostasis basically relies on the critical balance between cell
growth and cell death and is controlled by a myriad of signalling
networks. Asoutlined in this paper, numerous studieshavedemonstrated
dynamic changes in connexin-related signalling throughout this process,
andmore specifically in cell proliferation. Although it has been suggested
that these modifications are merely irrelevant side effects of cell cycling
[40,41,172], most investigators believe that a straightforward causal link
exists between connexin-related signalling and cell proliferation. As a
matter of fact, connexins and their channels actively control cell
proliferation at three communicative levels. At the intercellular level,
GJIC foresees the direct exchange of cell growth regulators between
Fig. 2. Connexin-related signalling in the control of cell proliferation. A number of connexin-akin mechanisms are involved in cell cycle regulation, comprising gap junctions (1),
connexin hemichannels (2–4), connexins (5–12) and pannexins (13–16). Gap junctions mediate the direct intercellular exchange of positive and negative cell growth regulators (1).
Hemichannels allow the extracellular liberation of ATP (2) and NAD+ (3). The former interacts with purinergic receptors of adjacent cells, which triggers production of IP3. The latter
is processed to cADPr and subsequently taken up by the cell through the ectoenzyme CD38. Both IP3 and cADPr bind to their corresponding receptors in the endoplasmic reticulum,
leading to release of calcium in the cytosol. A similar NAD+/cADPr pathway is observed intracellularly, whereby both CD38 and connexin hemichannels are located in vesicles (4).
Connexin proteins as such, particularly Cx43, can promote the degradation of the Skp2 protein (5) or can directly interfere with the gene expression of cell growth regulators in the
nucleus (6). Connexins colocalize with cadherins that maintain cell adhesion, which in turn favours cell growth arrest (7). Cx43 also interacts with another adherens junction
building stone, namely ß-catenin, being a critical component of the Wnt signalling cascade, known to affect cell cycling (8). Cx32 and Cx43 bind to Dlgh1 (9) and NOV (10),
respectively, that both influence cell growth. Connexins (i.e. Cx43) bind to the tight junction components ZO-2 (11) and ZO-1 (12) that interact with transcription factors, such as
AP-1 (c-jun/c-fos) and ZONAB, respectively, known to control the gene transcription of cell growth regulators. Panx1 and Panx2 present at the cell plasma membrane surface, the
Golgi apparatus or in the cytosol suppress cell proliferation (13). ATP and UDP can be extracellularly released through Panx1 hemichannels that, upon binding to purinergic receptors
at the cell plasma membrane surface, trigger a MAPK signalling cascade (14) or Gα12/13 proteins (15), ultimately resulting in the onset of cell growth. (AP-1, activator protein 1; ATP,
adenosine triphosphate; Ca2+, calcium; cADPr, cyclic adenosine diphosphate ribose; Cx, connexin; Dlgh1, discs-large homolog 1; IP3, inositol trisphosphate; MAPK, mitogen-
activated protein kinase; NAD+, nicotinamide adenine dinucleotide; NOV, nephroblastoma overexpressed; Panx, pannexin; Skp2, S phase kinase-associated protein 2; UDP, uridine
diphosphate; ZO-1/2, zonula occludens 1/2; ZONAB, ZO-1-associated nucleic acid binding protein).
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adjacent cells. At the extracellular level, connexinhemichannels allow the
paracrine release of homeostasis regulatory proteins. At the intracellular
level, connexin proteins can directly or indirectly affect the production of
cell cycle regulators or can act as a cellular signalling reservoir by
reversibly interacting with these substances. In recent years, pannexins
have also joined in as regulators of the homeostatic balance, which they
can affect as either single units or as channel entities (Fig. 2). Although
exceptions exist, it could be stated that gap junctions and connexin/
pannexin protein actions are generally associated with suppression of
proliferative activity, whereas hemichannels rather promote cell cycling.
This suggests differential regulation depending on the connexin/
pannexin assembly status, a principle that has already been elegantly
demonstrated in the case of phosphorylation of Cx43 [106,107]. It is
tempting to speculate that other posttranslational modifications might
also play a role in this process. Cx26, for instance,was recently found to be
a substrate for acetylation, hydroxylation, γ-carboxyglutamation and
methylation [291]. Considerable differences in this respect equally exist
between the two types of channel-forming proteins, since pannexins,
unlike connexins, can be glycosylated [292,293]. The many connexin-
binding proteins, the so-called gap junction proteome [14], that still
continue to be discovered are likely to be involved in the distinct
regulation of connexin/pannexin channels as well. Collectively, such
actions could alter channel permeability which in turn might allow fine-
tuned selection of cell growth messenger traffic. A number of other
mechanisms that might underlie connexin-related control of cell
proliferation also await exploitation. In this respect, microRNA species
have recently entered the connexin arena at the posttranscriptional
platform [26–31], though its relevance to cell cycle management has not
yet been documented. Inversely, the intrinsic functions of connexin
proteins in the control of cell cycle regulator gene transcription also
deserve further scrutiny. It will be of the utmost importance to establish
the relative importance of each of thesemechanisms under physiological
and pathological circumstances, as thus far the majority of studies in this
field have used cancerous or transformed cells, both in in vivo and in vitro
settings. An equally important and even more fundamental challenge
concerns the elucidation of the exact contribution of gap junctions and
hemichannels composed of either connexins or pannexins to cell
proliferation. This research is currently hampered by the ubiquitous
lack of appropriate testing approaches that enable unequivocal discrim-
ination between the different channel types and its constituents,
especially in an in vivo environment [21,294]. Thus, many acknowledged
gap junction inhibitors, including carbenoxolone, also inhibit connexons
and pannexin channels [19]. Such constraints similarly hold true for
certain connexin mimetic peptides that are claimed to be specific
connexin hemichannel inhibitors, but which additionally suppress GJIC
depending on the time frame of application [295]. It can be anticipated
that upon introduction of appropriate experimental tools, more insight
will be gained into the molecular mechanisms that drive connexin-
related signalling in cell cycle control.
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